Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 3 4Phase 1/2 4Phase 2/3 1Phase 1 1

Status

Unknown 3Recruiting 1

Sponsor Class

OTHER 3OTHER_GOV 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Carcinoma, Hepatocellular 5Triple Negative Breast Neoplasms 4Neoplasms 2Esophageal Squamous Cell Carcinoma 2Biliary Tract Neoplasms 2Advanced Gastric Cancer 2Urinary Bladder Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Respiratory Tract Diseases 1Recurrence 1Rectal Neoplasms 1Pyloric Stenosis, Hypertrophic 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Effusion, Malignant 1Pancreatic Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Lung Diseases 1Locally Advanced or Metastatic Solid Tumors 1Locally Advanced or Metastatic Gastric Adenocarcinoma 1Hepatic Metastasis of Colorectal Cancer 1Esophageal Neoplasms 1Disease Progression 1Colorectal Neoplasms 1Colorectal Cancer Recurrent 1Carcinoma, Non-Small-Cell Lung 1CRC 1

Interventions

pembrolizumab 30Nivolumab 15Paclitaxel 13Cyclophosphamide 12Carboplatin 12sacituzumab govitecan 8Cisplatin 8Capecitabine 7130-nm albumin-bound paclitaxel 7Gemcitabine 6fludarabine 5durvalumab 5avelumab 5atezolizumab 5Magnetic Resonance Spectroscopy 5Ipilimumab 5Biopsy 5camrelizumab 4Specimen Handling 4Interleukin-2 4Injections 4Immune Checkpoint Inhibitors 4Docetaxel 4toripalimab 3talazoparib 3Leucovorin 3Everolimus 3Clinical Trials, Phase II as Topic 3Bevacizumab 3yeast-CEA vaccine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Triple Negative Breast Neoplasms × camrelizumab × Clear all
NCT05928780 2023-07-03

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)

Fudan University

Phase 1/2 Unknown
125 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03805399 2022-08-10

FUTURE

Fudan University

Phase 1/2 Unknown
140 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04481763 2020-07-22

A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast

Jiangxi Provincial Cancer Hospital

Phase 1/2 Recruiting
20 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04213898 2019-12-30

SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer

Henan Cancer Hospital

Phase 1/2 Unknown
39 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡